The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
ApexOnco Front Page
Recent articles
The company will license EGFR and cMet inhibitors from Celyn.
The company discontinues its Yap/TEAD inhibitor IAG933 owing to lack of tolerability and efficacy.
The second-line Litespark-011 and adjuvant Litespark-022 trials are apparently hits.
Early data with the RIPTAC HLD-0915 look competitive.
The G12D-preferring QTX3034 has produced responses in endometrial and colorectal cancers.
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
